BioNTech (BNTX) PT Lowered to $140 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BNTX Hot Sheet
Price: $90.38 +3.98%
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
Wells Fargo analyst Mohit Bansal lowered the price target on BioNTech (NASDAQ: BNTX) to $140.00 (from $150.00) while maintaining a Overweight rating.
You May Also Be Interested In
- BioNTech (BNTX) PT Lowered to $106 at Morgan Stanley
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
- BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
